Ocugen finds no lesion-size benefit in OCU410ST review

Ocugen said an independent review of 26 OCU410ST patients found no lesion-size benefit, while the study will continue with added resources and a retinal CMO. The company targets GARDian3 12-month top-line in Q2 2027 and is advancing late-stage therapies including OCU400 and OCU410ST.